Mesoblast's Cell Therapy Strengthens Native Heart Function In Patients With End-Stage Heart Failure on Assisted Circulatory Support
18. November 2013 18:14 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Patients with end-stage or New York Heart Association (NYHA) class IV heart failure who receive a surgically implanted left...
IMPROVED SURVIVAL IN CHILDREN WITH LIFE THREATENING GRAFT VERSUS HOST DISEASE REPORTED AFTER TREATMENT WITH MESOBLAST'S CELL THERAPY
13. November 2013 19:22 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that a peer-reviewed article in the...
Mesoblast's Mesenchymal Precursor Cells Induce Functional Recovery in Ischemic Stroke Model
11. November 2013 06:00 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced positive preclinical trial results which...
FDA CLEARS COMMENCEMENT OF PHASE 3 CHRONIC HEART FAILURE TRIAL USING MESOBLAST'S PROPRIETARY CELLS
30. Oktober 2013 18:41 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Food and Drug...
MESOBLAST UPDATES MARKET ON REGISTRATION PLANS FOR GVHD CELL PRODUCT IN JAPAN
28. Oktober 2013 01:11 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today updated the market on product registration plans in...
Mesoblast, Intrexon and ZIOPHARM to Target Cancers
23. Oktober 2013 18:28 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB), a world leader in the development of cell-based biologic products, Intrexon Corporation (NYSE: XON),...
MESOBLAST ACQUIRES OSIRIS' CULTURE EXPANDED STEM CELL THERAPEUTIC BUSINESS
10. Oktober 2013 20:28 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Oct. 10, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced the acquisition of the entire...
Mesoblast's Phase 2 Trial For Lumbar Spinal Fusion Selected For Presentation at Premier Spine Conference
18. September 2013 23:02 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the Phase 2 clinical trial using the...
Mesoblast's Strong Cash Position Enables Execution of Late-Stage Clinical Trials
29. August 2013 00:42 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 29, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company, Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY), today provided its full year financial results. The...
Mesoblast Receives $4.3 Million from Australian Government for Adult Stem Cell Pipeline Development
18. Juli 2013 00:26 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, July 18, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited today announced that it has received approximately $4.3 million under the Australian Government's Innovation...